Pulmonary Arterial Hypertension Market to Grow Positively at a Paltry CAGR During the Study Period | Insmed Incorporated, and others expected to boost the market

DelveInsight's "Pulmonary Arterial Hypertension - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Pulmonary Arterial Hypertension market share of the individual therapies, current and forecasted Pulmonary Arterial Hypertension market size from 2020 to 2034 segmented by seven major markets. The report also offers current Pulmonary Arterial Hypertension therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Pulmonary Arterial Hypertension market.
Request for a sample report @ https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the Pulmonary Arterial Hypertension Market Report:

The prevalence of Pulmonary Arterial Hypertension (PAH) has been rising, largely due to increasing rates of cardiovascular diseases and arterial hypertension, as well as a growing adult population more susceptible to idiopathic PAH. This trend is contributing to a higher incidence of PAH cases.
The PAH market is expected to see steady growth from 2023 to 2034, driven by the expanding patient population. In the seven major markets (7MM), the market size for PAH is projected to rise as the prevalence of the condition grows.
The US FDA has approved several therapies for PAH, including UPTRAVI (selexipag), REMODULIN (treprostinil), TYVASO (treprostinil), ORENITRAM (treprostinil), and ADEMPAS (riociguat). Additionally, generics of previously approved drugs, such as REVATIO (sildenafil), ADCIRCA (tadalafil), LETAIRIS/VOLIBRIS (ambrisentan), VENTAVIS (iloprost), TRACLEER (bosentan), BERAPROST (TRK-100), and VELETRI (epoprostenol), are available.
Current mainstay therapies for PAH focus on dilating the pulmonary vasculature, which reduces pulmonary vascular resistance and improves right ventricular function, ultimately enhancing functional capacity. The primary goals of treatment are to improve survival, quality of life, exercise capacity, and symptom management, with risk stratification tools increasingly guiding therapy decisions.
In 2022, the US held the largest share of the PAH market among the 7MM, with a market size of approximately USD 3,898.5 million, and this figure is expected to grow by 2034.
Among the various therapies, UPTRAVI, developed by Johnson & Nippon, stands out as the only prostacyclin receptor agonist and the newest entrant in the market. Available in both tablet and IV injection forms, UPTRAVI generated USD 1,101.7 million in revenue in 2022, representing 28% of the total PAH market in the US.
Significant advancements in research, a deeper understanding of the disease, and technological progress are expanding clinical knowledge and leading to the development of new therapies. Emerging treatments, such as United Therapeutics' ralinepag and Respira Therapeutics' vardenafil (RT234), are in development and are anticipated to enter the market during the forecast period, introducing new competition in the PAH treatment landscape.
Ralinepag, an oral, selective, and potent prostacyclin receptor agonist developed by United Therapeutics, is expected to be a significant competitor when it launches in the US in 2025.

Pulmonary Arterial Hypertension Overview

Pulmonary Arterial Hypertension (PAH) is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It is characterized by elevated blood pressure in the pulmonary arteries, which are the vessels that carry blood from the heart to the lungs. This increased pressure makes it harder for the heart to pump blood through the lungs, leading to a range of symptoms and complications.

Causes

PAH can be classified into several categories based on its causes:

1. Idiopathic PAH:
- No identifiable cause. This is the most common form of PAH.

2. Heritable PAH:
- Genetic mutations or family history contribute to the development of PAH.

3. Associated PAH:
- Connective Tissue Diseases: Conditions like scleroderma or lupus.
- Congenital Heart Disease: Such as left-to-right shunt defects.
- HIV Infection: Can lead to PAH.
- Portal Hypertension: Associated with liver disease.
- Schistosomiasis: A parasitic infection that can affect the pulmonary arteries.
- Other Conditions: Including severe obstructive sleep apnea or certain inflammatory diseases.

4. Group 2 (Secondary to Left Heart Disease):
- Elevated pulmonary pressures due to left heart conditions, such as left ventricular dysfunction or mitral valve disease. While not classified as PAH, this can be related.

Signs and Symptoms

The symptoms of PAH can be progressive and may include:

- Shortness of Breath (Dyspnea): Especially during exertion, but can also occur at rest in advanced stages.
- Fatigue: General tiredness and decreased ability to perform physical activities.
- Chest Pain: Discomfort or pain in the chest, often due to strain on the heart.
- Palpitations: Sensation of a rapid or irregular heartbeat.
- Swelling (Edema): Fluid retention in the legs, ankles, or abdomen.
- Cyanosis: Bluish discoloration of the lips or skin due to low oxygen levels.
- Dizziness or Syncope: Lightheadedness or fainting, particularly with exertion.

Diagnosis

Diagnosing PAH involves several steps:

1. Clinical Evaluation:
- Medical History: Assessment of symptoms, risk factors, and family history.
- Physical Examination: Checking for signs like a loud second heart sound (P2) or signs of right-sided heart failure.

2. Laboratory Tests:
- Blood Tests: To rule out secondary causes of PAH and assess overall health (e.g., liver function tests, kidney function tests, and markers of connective tissue diseases).

3. Imaging Studies:
- Chest X-ray: To identify signs of heart enlargement or lung abnormalities.
- Echocardiography: Provides an assessment of right heart function and estimates pulmonary artery pressure.

4. Specialized Testing:
- Right Heart Catheterization: The gold standard for diagnosing PAH, involving the measurement of pulmonary artery pressure and cardiac output.
- Pulmonary Function Tests: To assess lung function and rule out other causes of breathlessness.
- Ventilation/Perfusion (V/Q) Scan: To rule out pulmonary embolism as a cause of elevated pressures.

5. Additional Studies:
- CT Pulmonary Angiography: To visualize pulmonary arteries and identify other conditions like chronic thromboembolic disease.
- MRI: For detailed imaging of the heart and blood vessels if needed.

Treatment Options

The management of PAH focuses on alleviating symptoms, improving quality of life, and slowing disease progression. Treatment may include:

1. Medications:
- Endothelin Receptor Antagonists (ERAs): Such as bosentan or ambrisentan, which help relax and dilate blood vessels.
- Phosphodiesterase-5 Inhibitors: Like sildenafil or tadalafil, which improve blood flow by relaxing smooth muscle in the pulmonary arteries.
- Prostacyclin Analogs: Such as epoprostenol or treprostinil, which dilate pulmonary and systemic arterial vascular beds.
- Soluble Guanylate Cyclase Stimulators: Like riociguat, which helps to relax blood vessels and lower blood pressure in the lungs.
- Diuretics: To manage fluid retention and swelling.
- Anticoagulants: In certain cases, to prevent blood clots, especially if there is evidence of thromboembolism.

2. Non-Pharmacological Therapies:
- Oxygen Therapy: To maintain adequate oxygen levels, especially during physical activity or at night.
- Pulmonary Rehabilitation: Exercise programs and education to improve physical function and quality of life.

3. Procedural Interventions:
- Atrial Septostomy: A surgical procedure to create a small hole between the atria of the heart, which can help reduce symptoms in severe cases.
- Lung Transplantation: Considered in advanced cases where other treatments are not effective.

4. Lifestyle Modifications:
- Salt Restriction: To reduce fluid retention and manage swelling.
- Regular Monitoring: Ongoing follow-up with healthcare providers to adjust treatment as needed and monitor disease progression.

Prognosis

The prognosis for PAH varies depending on the severity of the condition, the underlying cause, and the response to treatment. Advances in medical therapy and treatment options have improved the outlook for many patients. However, PAH remains a serious condition with potential for significant impact on quality of life and overall health. Early diagnosis and appropriate management are crucial for improving outcomes and prolonging survival. Regular follow-up and adherence to treatment plans are essential for optimizing care and managing the disease effectively.

Pulmonary Arterial Hypertension Epidemiological Insights
According to DelveInsigt's estimates, the total 7MM prevalent population of Pulmonary Arterial Hypertension were 69,605 cases in 2021.
Download PAH Market report sample PDF @ https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Pulmonary Arterial Hypertension Treatment Market
Treatment of Pulmonary arterial hypertension (PAH) has progressed significantly over the past few decades in both its complexity and efficacy. The therapy aims to achieve a low-risk status (maintaining WHO-FC II if possible) to preserve patient function, quality of life and minimize mortality risk. This is generally achieved by optimizing the patient's 6 minute walk distance (6MWD); however, current target thresholds rely upon cohort studies and expert consensus.
Promising Therapies in the Pulmonary Arterial Hypertension Pipeline
Treprostinil Palmitil
And others
Discover more about Pulmonary Arterial Hypertension therapies in the pipeline @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Pulmonary Arterial Hypertension Market
Insmed Incorporated
And others
To understand key companies related to the Pulmonary Arterial Hypertension Market, get a snapshot of the Pulmonary Arterial Hypertension Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Pulmonary Arterial Hypertension Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Pulmonary Arterial Hypertension Companies: Insmed Incorporated, and others
Key Pulmonary Arterial Hypertension Pipeline Therapies: Treprostinil Palmitil, and others
Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and emerging therapies
Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Pulmonary Arterial Hypertension Market Access and Reimbursement
Table of Contents
1. Pulmonary Arterial Hypertension Market Key Insights
2. Pulmonary Arterial Hypertension Market Report Introduction
3. Pulmonary Arterial Hypertension Market Overview at a Glance
4. Pulmonary Arterial Hypertension Market Executive Summary
5. Disease Background and Overview
6. Pulmonary Arterial Hypertension Treatment and Management
7. Pulmonary Arterial Hypertension Epidemiology and Patient Population
8. Patient Journey
9. Pulmonary Arterial Hypertension Emerging Drugs
10. 7MM Pulmonary Arterial Hypertension Market Analysis
11. Pulmonary Arterial Hypertension Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Pulmonary Arterial Hypertension Market Drivers
15. Pulmonary Arterial Hypertension Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight:

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.